Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTPRG | P23470 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787325 | 0.83 | ALDH1A1 (0.60) | RAB9AALDH1A1NPC1TP53SMN1; SMN2 | |
| SCHEMBL16927708 | 0.80 | HTT (0.63) | ALDH1A1SMN1; SMN2GAAPOLBKMT2A | |
| SCHEMBL1785320 | 0.79 | KDR (0.63) | RAB9AALDH1A1NPC1CYP1A2POLB | |
| SCHEMBL1786964 | 0.78 | PKM (0.55) | ALDH1A1POLBTDP1KMT2AMEN1 | |
| SCHEMBL1800354 | 0.76 | PTPRC (0.53) | RAB9APRNPALDH1A1PTPRGGAA | |
| SCHEMBL28424352 | 0.76 | RAB9A (0.56) | RAB9APRNPALDH1A1NPC1TP53 | |
| SCHEMBL28566212 | 0.75 | RAB9A (0.55) | RAB9APRNPALDH1A1NPC1TP53 | |
| SCHEMBL10802624 | 0.73 | CYP1A2 (0.48) | RAB9APRNPALDH1A1NPC1TP53 | |
| SCHEMBL1496296 | 0.71 | ALDH1A1 (0.51) | RAB9APRNPALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL15143209 | 0.71 | CYP1A2 (0.65) | RAB9APRNPALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8507485-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7906511-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1864977-A1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | AGTR1, AGTR2, ARRB1 | RAB9A 2641/4885PRNP 3614/4885ALDH1A1 134/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | RAB9A 3160/4885PRNP 2701/4885ALDH1A1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.